ELTX ANGION BIOMEDICA CORP

Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on December 6, 2023 at 10:30 AM ET.

A live webcast of the presentation will be accessible under “” in the Investors section of Elicio’s and will be available on-demand for 90 days following the event.

About Elicio Therapeutics

Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. By combining expertise in immunology and immunotherapy, Elicio is engineering investigational Amphiphile (AMP) immunotherapies intended to precisely target and fully engage the lymph nodes, the site in our bodies where the immune response is orchestrated. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers.

Media Contact

Kristin Politi

LifeSci Communications



973-495-5221

Investor Relations Contact

Heather DiVecchia

Elicio Therapeutics



857-209-0153

 



EN
04/12/2023

Underlying

ELTXANGION BIOMEDICA CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ANGION BIOMEDICA CORP

 PRESS RELEASE
Free
ELTX ANGION BIOMEDIC...

Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Disc...

Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer BOSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will host a virtual key opinion leader (“KOL”) event on Wednesday, June 25, 2025 at 2:00 PM ET to discuss the significant unmet need and current treatment landscape for mutant-KRAS (“mKRAS”) ...

June 17, 2025 1 EN
 PRESS RELEASE
Free
ELTX ANGION BIOMEDIC...

Elicio Therapeutics Secures $10 Million in Financing

Elicio Therapeutics Secures $10 Million in Financing Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has entered a $10 million senior secured promissory note (the “Note”) with existing investor, GKCC, LLC (“Note Holder” or “GKCC”) (the “Note Financing”). The proceeds f...

June 4, 2025 1 EN
 PRESS RELEASE
Free
ELTX ANGION BIOMEDIC...

Elicio Therapeutics Reports First Quarter 2025 Financial Results and P...

Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates Interim analysis focused on disease-free survival (“DFS”) in randomized Phase 2 AMPLIFY-7P clinical trial expected in Q3 2025 Company has alignment with U.S. Food and Drug Administration (“FDA”) on key design elements of planned Phase 3 study of ELI-002 Current cash position expected to support operations beyond anticipated AMPLIFY-7P Phase 2 interim analysis BOSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage b...

May 13, 2025 1 EN
 PRESS RELEASE
Free
ELTX ANGION BIOMEDIC...

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and...

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires BOSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on April 15, 2025, Elicio granted inducement awards to Elicio’s newly appointed Chief Strategy and Financial Officer, Preetam Shah, and two additional new employees, as an inducement material to Dr. Shah and such employees enterin...

April 16, 2025 1 EN
 PRESS RELEASE
Free
ELTX ANGION BIOMEDIC...

Elicio Therapeutics Reports 2024 Financial Results and Provides Corpor...

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis expected in Q3 2025 Aligned with U.S. Food and Drug Administration (“FDA”) on key elements of planned ELI-002 Phase 3 study design, including dose, patient population and primary endpoint analysis Strengthened cash position to support operations beyond the anticipated AMPLIFY-7P Phase 2 interim analysis BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, ...

March 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch